menu

Autologous Hematopoietic Stem Cell Transplantation and Mobilization in Multiple Myeloma: Current Debate and Developments: Part 2

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Autologous Hematopoietic Stem Cell Transplantation and Mobilization in Multiple Myeloma: Current Debate and Developments: Part 2

Join two experts as they discuss developments in ASCT for the treatment of multiple myeloma. This activity is Part 2 of 2.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    In the age of immunomodulatory agents, proteasome inhibitors, and other novel agents for the treatment of multiple myeloma (MM), the role of autologous hematopoietic stem cell transplantation (ASCT) has become an area of debate. Whereas most oncologists recognize a role for ASCT in the up-front treatment of MM, this view is not universally shared, particularly when it comes to treating younger patients with MM (<65 years old). Comorbidities were cited in a recent survey of perceptions and practices of oncologists and transplant specialists as the most frequent reason younger patients with a clinical indication for ASCT would not be referred to a transplant specialist. Although advanced age and comorbidities can limit eligibility for ASCT, these concerns are not absolute contraindications for ASCT. The use of plerixafor and captisol-enabled melphalan are advancing the limits of what can be achieved by ASCT in patients with MM.

    This activity is a web-based, on-demand activity, featuring an expert panel discussion. This activity is designed as a forum for the debate and evaluation of the most recent clinical data, and to provide evidence-based updates and expert insights on the discussion points to translate current and emerging evidence into real-world clinical practice.

    Prior to beginning Part 2 of this activity, please complete Part 1.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Review outcome data for patients with multiple myeloma who receive versus those who do not receive autologous hematopoietic stem cell transplantation
    • Compare data between patients with multiple myeloma who receive early versus delayed autologous hematopoietic stem cell transplantation
    • Discuss guidelines about the recommended timing and eligibility for autologous hematopoietic stem cell transplantation
    • Consider data regarding the impact of comorbidities on the utility of autologous hematopoietic stem cell transplantation for patients with multiple myeloma
    • Choose mobilization strategy based on patient-specific needs and drug-specific characteristics
    • Compare stem cell mobilization and transplantation efficacy with standard melphalan to captisol-enabled melphalan and other drugs used for induction therapy in patients with multiple myeloma
    • Compare the safety profiles of standard melphalan to captisol-enabled melphalan and other drugs used for induction therapy in patients with multiple myeloma
  • Target Audience

    This activity is intended for hematologists, transplant specialists, and other clinicians.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
    Parameswaran Hari, MD, reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Celgene Corporation, Sanofi, Bristol-Myers Squibb Company, Spectrum Pharmaceuticals, Inc, and Takeda Pharmaceutical Company; Kite Pharmaceuticals; Research grant, Takeda Pharmaceutical Company.
    Nina Shah, MD, reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Takeda Oncology, Celgene Corporation, Indapta Corporation; Received income in any amount from, Celgene Corporation.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
    The following AXIS planners and managers, Linda Gracie-King, MS, and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credist Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

  • Commercial Support

    This activity is supported by an educational grant from Sanofi Genzyme.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.